Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...